Plus   Neg

Bristol-Myers Squibb (BMY) Has Set A New High After Phase 3 Study Stopped Early

Bristol-Myers Squibb (BMY) announced Sunday that it has put an early stop to its Phase 3 study of Opdivo versus docetaxel, in previously treated patients with advanced, squamous cell non-small cell lung cancer. The independent Data Monitoring Committee had determined that the study met its endpoint, demonstrating superior overall survival.

Bristol-Myers Squibb gapped open sharply higher Monday morning and is now up 2.05 at $62.37. The stock has risen above a 2 1/2 month trading range and has set a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT